Pharmaceutical Technology

SEPTEMBER 22, 2022

According to the partnership, Celltrion will oversee the development of ABP 102, after Abpro concludes in vitro studies, as well as hold the global marketing rights. To create these antibodies, the platform merges next-generation sequencing, nano-immunology, superior engineering and bioinformatics.

Antibody 130

Antibody Development Bioinformatics In-Vitro 130

Drug Discovery World

JULY 27, 2023

In a DDW Sitting Down With podcast with Lu Rahman, Ruth Roberts and Claire Sadler , ApconiX, discuss the benefits of performing a target safety assessment (TSA) during drug discovery and development when a biological target is going to be acted on by a drug. Over 40% of drug safety failures are due to the drug target.

Bioinformatics 52

Bioinformatics Drugs In-Vitro Development 52

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. These tumor-derived entities are used to derive genomic and proteomic data. The same webinar held a Q&A session with Dr. Bahassi and two other experts from Medpace, Dr. Lyon L.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Scienmag

AUGUST 31, 2020

The project seeks to kickstart the development of an open access “Organoid Cell Atlas” By creating well-characterized in vitro […].

In-Vitro 98

In-Vitro Research Development Bioinformatics 98

Drug Discovery World

APRIL 21, 2023

The 2022 podium winner was Viktoria Zieger, Imtek – University of Freiburg, who presented: Selective High- Throughput Deposition of Microtumors for in vitro Studies on 3D Tumor Models. SLAS Europe 2023 will take place 22-26 May in Brussels, Belgium, where attendees will embrace the theme Science Set in Motion.

Doctors 52

Doctors Doctor Genetics In-Vitro 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Luncheon presentations will be given by Andrew Bradbury, MB BS, PhD, Chief Scientific Officer, Specifica, and Stefanie Kall, Ph.D.,

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

OCTOBER 17, 2022

It takes the right skill set, good information, and the ability to change course as needed. In today’s quest to accelerate time to market for novel drugs, part of the success formula requires leveraging discovery data with more precision and speed, and earlier in the process. Trying to do data science with mixed media files is even worse.

Marketing 52

Marketing Scientist Gene Expression Drugs 52